EditorialKommentar
1+2 Might Be >2
JACC: Heart Failure · 2024-01 · 12 (1) · 222-225
DOI: 10.1016/j.jchf.2023.08.007 ↗Kurz gefasst
Editorial in der Zeitschrift JACC: Heart Failure, 2024-01. Verfasst von Bertram Pitt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Heart Failure, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Heart FailureDiabetes Mellitus, Type 2Renal Insufficiency, ChronicHumansHypoglycemic Agents
Stichwörter der Autor:innen
SGLT inhibitionchronic kidney diseaseheart failuresotagliflozintype 2 diabetes
Substanzen
Hypoglycemic Agents
Autor:innen und Institutionen
- Division of Cardiology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
- Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: dlbhattmd@post.harvard.edu.
Zitieren
APA
Pitt, B., & Bhatt, D. L. (2024). 1+2 Might Be >2. JACC: Heart Failure, 12(1), 222-225. https://doi.org/10.1016/j.jchf.2023.08.007
Vancouver
Pitt B, Bhatt DL. 1+2 Might Be >2. JACC: Heart Failure. 2024;12(1):222-225. doi:10.1016/j.jchf.2023.08.007
BibTeX
@article{Pitt2024,
author = {Pitt, Bertram and Bhatt, Deepak L},
title = {1+2 Might Be >2},
journal = {JACC: Heart Failure},
year = {2024},
volume = {12},
number = {1},
pages = {222--225},
doi = {10.1016/j.jchf.2023.08.007}
}
EUVIMED